Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences , Soochow University , Su Zhou , Jiangsu 215021 , P. R. China.
ACS Chem Neurosci. 2019 Feb 20;10(2):783-791. doi: 10.1021/acschemneuro.8b00313. Epub 2018 Sep 21.
Parkinson's disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015-2018) on adenosine receptor A antagonists and discuss the challenge and opportunity for the treatment of PD.
帕金森病（PD）是一种神经退行性疾病，存在着大量未得到满足的医疗需求。目前以多巴胺为中心的治疗方法旨在恢复患者的运动功能，而不会减缓疾病进展。这些药物的长期使用与疗效降低、运动波动和运动障碍有关。此外，多巴胺能治疗方法对与 PD 相关的非运动特征（如睡眠障碍、疼痛和精神症状）的治疗效果较差。在过去的十年中，腺苷受体 A 拮抗剂已成为治疗 PD 的潜在药物。在这里，我们总结了 2015 年至 2018 年期间关于腺苷受体 A 拮抗剂的最新研究工作，并讨论了治疗 PD 的挑战和机遇。
